 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
22 News |  |
- || Review, Journal: Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs. (Pubmed Central) - Mar 11, 2024
Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, solabegron, vibegron, olorinab, ebastine, and ORP-101 have demonstrated possible effects but remain confirmed...Therefore, we should focus on developing new, efficient, and affordable medications for IBS-D. The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment.
- || Ibodutant (MEN 15596) / Menarini, Mytesi (crofelemer) / Jaguar Health
Review, Journal: Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review. (Pubmed Central) - Mar 25, 2021
Due to the limited number of studies per treatment option, no recommendations can be made on the choice of a specific treatment. It is clear, however, that so as not to miss beneficial treatment options for either sex, the inclusion, analysis and description of data on the basis of sex is of the utmost importance.
- | Ibodutant (MEN 15596) / Menarini
Journal: Gender-related differences of tachykinin NK receptor expression and activity in human colonic smooth muscle. (Pubmed Central) - Dec 16, 2020
In patients with diarrhea-predominant irritable bowel syndrome, the NK receptor antagonist ibodutant had a greater therapeutic effect in females than males...These factors may underlie the gender differences in the treatment of diarrhoea-predominant irritable bowel syndrome with NK2 receptor antagonists. Our findings highlight that gender differences should be considered in the therapeutic development of NK2 receptor agents.
- | Ibodutant (MEN 15596) / Menarini
Journal: The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. (Pubmed Central) - Aug 22, 2019
The promising results were not replicable and confirmed in phase III of clinical trials. Ibodutant is not ready to be introduced in the pharmaceutical market and further studies on alternative NK2 antagonist are needed to make NK2 antagonists useful tools in IBS-D treatment.
- | Ibodutant (MEN 15596) / Menarini
Trial termination: IRIS-4: 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - May 19, 2016
P3, N=500, Terminated, Sponsor: Menarini Group
Ibodutant is not ready to be introduced in the pharmaceutical market and further studies on alternative NK2 antagonist are needed to make NK2 antagonists useful tools in IBS-D treatment. Active, not recruiting --> Terminated; Because of negative results of the sister study NAK-06 and the low overall response rate at week 24.
- Ibodutant (MEN 15596) / Menarini
Enrollment change, Trial withdrawal: IRIS-05: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - May 19, 2016
P3, N=0, Withdrawn, Sponsor: Menarini Group
Active, not recruiting --> Terminated; Because of negative results of the sister study NAK-06 and the low overall response rate at week 24. N=500 --> 0 | Suspended --> Withdrawn
- | Ibodutant (MEN 15596) / Menarini
Trial completion: IRIS-3: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Jul 15, 2015
P3, N=500, Completed, Sponsor: Menarini Group
N=500 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed
- || Ibodutant (MEN 15596) / Menarini
Trial suspension: IRIS-05: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Apr 14, 2015
P3, N=500, Suspended, Sponsor: Menarini Group
Active, not recruiting --> Completed Not yet recruiting --> Suspended
- ||||| Ibodutant (MEN 15596) / Menarini
Enrollment closed, Trial primary completion date: IRIS-4: 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Apr 9, 2015
P3, N=500, Active, not recruiting, Sponsor: Menarini Group
Not yet recruiting --> Suspended Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Oct 2015
- ||||| Ibodutant (MEN 15596) / Menarini
Trial initiation date: IRIS-05: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Mar 14, 2015
P3, N=500, Not yet recruiting, Sponsor: Menarini Group
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Oct 2015 Initiation date: Oct 2014 --> Oct 2015
- ||||| Ibodutant (MEN 15596) / Menarini
Enrollment closed: IRIS-3: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Jan 22, 2015
P3, N=500, Active, not recruiting, Sponsor: Menarini Group
Initiation date: Oct 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- |||||||||| Ibodutant (MEN 15596) / Menarini
New P3 trial: IRIS-05: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Dec 19, 2014
P3, N=500, Recruiting, Sponsor: Menarini Group
- |||||||||| Ibodutant (MEN 15596) / Menarini
New P3 trial: IRIS-4: 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Apr 20, 2014
P3, N=500, Recruiting, Sponsor: Menarini Group
- |||||||||| Ibodutant (MEN 15596) / Menarini
New P3 trial: IRIS-3: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Apr 6, 2014
P3, N=500, Recruiting, Sponsor: Menarini Group
- |||||| Ibodutant (MEN 15596) / Menarini
Enrollment open: IRIS-3: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Apr 3, 2014
P3, N=500, Recruiting, Sponsor: Menarini Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Ibodutant (MEN 15596) / Menarini
Trial completion: IRIS-2: Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D) (clinicaltrials.gov) - Jul 5, 2012
P2, N=565, Completed, Sponsor: Menarini Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed